Upbeat phase II news lately from Spyre Therapeutics Inc. in inflammatory bowel disease (IBD) perked not only the company’s stock but also wider interest in the buzzing space, where developers big and small are trying to tackle such chronic bedevilments as Crohn’s disease and ulcerative colitis (UC).